



1901 Avenue of the Stars, 2nd Floor Los Angeles, CA 90067



(530) 231-7800



info@vitality.bio



Key Near-Term Milestones

- ✓ Phase 1 clinical trial (1H 2019)
- ✓ Phase 2 initiation (2H 2019)
- ✓ Launch of Vitality Healthtech Opiate Reduction Centers (1H 2019)

Ticker: VBIO

Financial Highlights

Recent financing (Oct. 2018):

\$8.5M in common stock & warrants

Management Team



Robert Brooke
CEO & Co-founder

Bioengineer, former hedge fund analyst, Founder of biotech now known as Iovance Bio (NASDAQ:IOVA), Georgia Tech, UCLA




Richard McKilligan, JD, MBA
Controller & Counsel

CA and NY bar, former CPA. JD from Cornell, MBA from Univ. of Chicago



Brandon Zipp, PhD
Director, Research & Development
Scientific Co-founder

>12 years R&D, Cannabosides inventor, PhD in Plant Sciences, UC Davis.



Dr. Reef Karim
Chief Medical Officer,
Vitality Healthtech

Board certified physician in addiction medicine and psychiatry, CNN correspondent

Company Overview

Vitality Biopharma is unlocking the power of cannabinoid pharmaceuticals for treatment of serious neurological and inflammatory conditions. The Company's operations include federally-compliant cannabinoid drug development and the launch of a specialty care treatment network in the United States focused on the reduction of opioid dependence.

Investment Highlights



Novel Cannabinoid Pharmaceuticals Provide Targeted Delivery, Reducing Delivery Of Psychoactive THC to the Brain

Vitality has developed a proprietary new class of cannabinoid prodrugs named cannabosides, including VBX-100, a THC prodrug, which avoids psychoactivity through targeted GI delivery.

Independent clinical results suggest that cannabinoids will help induce remission in Crohn's disease, and that the vast majority of inflammatory bowel disease (IBD) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or pain.

Visiongain predicts that in 2018 drug revenues for treatment of IBD will reach \$9.6 billion. The ultimate goal of clinical treatment is to obtain complete disease control and to stop disease progression. This includes **remission of disease without use of steroids or opiates**, normalization of inflammatory markers, and healing of the mucosal lining of the gastrointestinal tract, leading to better clinical outcomes, reduced healthcare costs, and an improved quality of life.



1901 Avenue of the Stars, 2nd
Floor Los Angeles, CA 90067



(530) 231-7800



info@vitality.bio

Independent Directors



Hon. Edward Feighan
Chairman of the Board

Former Ohio congressman, Chair and CEO of Covius LLC, led ProCentury (NASDAQ:PROS) and Century Business Services (NYSE: CBZ)




Avtar Dhillon, MD
Member, Board of Directors

Former venture capitalist and family physician. Raised >\$200M in public markets. Led Inovio (NASDAQ: INO)



Michael Cavanaugh, JD, MBA, CPA, CFA
Member, Board of Directors

Private equity and special situations banking with Conway MacKenzie, Resilience Capital, Merrill Lynch.



Anthony Maida, PhD, MBA
Member, Board of Directors
Chair, Audit Committee

Extensive finance, operating, and clinical trials experience, Innovate Bioharma, Spectrum Pharmaceuticals, Lockheed

Investor Relations

Vitality Biopharma, Inc.
Phone: (530) 231-7800
Email: info@vitality.bio

Find out more online:

www.vitality.bio

Vitality Healthtech Specialty Care Operations to Combat US Opioid Epidemic



Reimagining the Future of Pain and Addiction Medicine Treatment with Use of Cannabinoid Therapies

Through Vitality Healthtech, a wholly-owned subsidiary, we are launching a network of specialty care treatment centers focused on opiate reduction, and pioneering use of cannabinoid therapies to help patients safely taper or eliminate use of opioid painkillers. The Company intends the Vitality Healthtech operations to be cashflow positive by 2020 and to have reached 100,000 or more patients within that timeframe.

Clinical Pipeline

Drug	Clinical Indications	Status
VBX-100	Inflammatory Bowel Disease (including remission)	Phase 1 trial to completed in 1 st half of 2019; Phase 2 trials to be initiated in 2 nd half of 2019
	Irritable Bowel Syndrome	
	Narcotic Bowel Syndrome	
VBX-210	Inflammatory Bowel Disease (maintaining remission)	Preclinical
	Irritable Bowel Syndrome	
	Opiate-Induced Bowel Dysfunction	
	C. Difficile Infections	
Additional Cannabinoid Formulations	Colorectal Cancer	Observational clinical studies to initiate in 1 st half of 2019
	Complex/Refractory or Neuropathic Pain (substitution therapy for opioid painkillers)	
	Autism	
	Multiple Sclerosis & Rare White Matter Disorders	
	Guillain-Barre	

This fact sheet contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our reports filed from time-to-time with the Securities and Exchange Commission.